

Datasheet for ABIN1399976

anti-HOXD9 antibody (AA 251-352) (FITC)



[Go to Product page](#)

Overview

Quantity:	100 µL
Target:	HOXD9
Binding Specificity:	AA 251-352
Reactivity:	Human
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This HOXD9 antibody is conjugated to FITC
Application:	Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Product Details

Immunogen:	KLH conjugated synthetic peptide derived from human HOXD9
Isotype:	IgG
Predicted Reactivity:	Human,Mouse,Rat,Dog,Cow,Pig,Chicken,Rabbit
Purification:	Purified by Protein A.

Target Details

Target:	HOXD9
Alternative Name:	HOXD9 (HOXD9 Products)
Background:	Synonyms: homeobox D9, Homeobox protein Hox D9, Hox 4.3, Hox 5.2, HOX4, HOX4C, RP23

Target Details

313J15.10, HXD9_HUMAN.

Background: The Hox proteins play a role in patterns of embryonic development and cellular differentiation by regulating downstream target genes. In vivo, the HoxD9 protein interacts with the autoregulatory and cross-regulatory enhancers of the murine HoxB1 and human HoxD9 genes. Specifically, the HoxD9 protein interacts with the human control region (HCR) of the HoxD9 gene, thus inducing transcription of the HoxD9 promoter. HoxD9 may be a multifunctional transcriptional regulator, as it contains different activation domains. Activation of HoxD9 depends on the structure of the target regulatory element, and results in differential cofactor interaction. The HoxD9 protein is expressed in the early stages of mouse joint development, primarily in the articular cartilage. HoxD9 transcripts are also detected in the synovial tissue of arthritic mice, but not in that of normal mice, suggesting that HoxD9 may have a role in the pathology of arthritis. Furthermore, the HoxD9 protein is highly expressed in the synoviocytes of patients with rheumatoid arthritis (RA), but not in osteoarthritis patients. The human HoxD9 protein is also differentially expressed in the human cervical cancer cell line HeLa, but is not expressed in the normal cervix and may thus play a role in tumorigenesis.

Application Details

Application Notes: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 µg/µL

Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Handling

Expiry Date: 12 months